HD Retatrutide 32 Pen

The HD Retatrutide 32 Pen is a high-strength research-peptide pen delivering 32 mg of retatrutide (LY3437943), Eli Lilly's investigational GLP-1/GIP/glucagon triple receptor agonist, currently in Phase 3 obesity trials under registrations including NCT06008783. For South African laboratory procurement in 2026, comparable 32 mg pens retail between roughly R2,940 and R4,950 across local suppliers. That pricing puts the format at the upper end of the local triple-agonist research market, higher than lower-concentration tirzepatide and semaglutide pens, which is expected given the total peptide mass and the compound's investigational status.

This page covers what the 32 mg high-dose pen format means for in vitro and preclinical dosing protocols. It explains how retatrutide's triple-receptor pharmacology differs from the dual-agonist (tirzepatide) and single-agonist (semaglutide) pens already circulating locally, and what South African researchers should verify before purchase, Certificate of Analysis (CoA) availability, high-performance liquid chromatography (HPLC) purity, and the South African Health Products Regulatory Authority's (SAHPRA) current regulatory posture on unregistered GLP-1 class compounds.

Key Takeaways

• The HD Retatrutide 32 Pen supplies 32 mg of a triple-agonist (GLP-1R/GIPR/GcgR) peptide in pre-filled pen format, priced between R2,940 and R4,950 locally.
• Retatrutide's glucagon-receptor arm distinguishes it from tirzepatide (dual agonist) and semaglutide (single agonist), making it the only locally available pen tool for energy-expenditure and hepatic-lipid studies.
• Phase 2 human data showed 24.2% mean body-weight reduction at 48 weeks on 12 mg once-weekly retatrutide, setting the translational benchmark for preclinical work.
• Research-grade certification requires ≥98% HPLC purity, mass-spectrometry identity confirmation, and cold-chain documentation; request batch-specific CoAs at quote stage.
• Retatrutide has no SAHPRA marketing authorisation; procurement for bona fide laboratory research is not prohibited, but human administration outside approved trials engages the Medicines and Related Substances Act.

What Is the HD Retatrutide 32 Pen?

The HD Retatrutide 32 Pen is a pre-filled research-peptide pen containing 32 mg of retatrutide (LY3437943), Eli Lilly's investigational GLP-1/GIP/glucagon triple receptor agonist. It is supplied in a single high-dose cartridge for in vitro and preclinical handling. The "HD" prefix denotes the high-dose product line, distinguishing the 32 mg format from lower-strength pens and vials sold locally, including 30 mg pen and R1,600 vial alternatives that carry the same total compound in different delivery formats.

For procurement officers, the practical appeal is aliquot economy. A single 32 mg pen drawn into 1 mg working aliquots yields approximately 32 research units per cartridge. That reduces reconstitution steps compared to lyophilised vials and lowers per-aliquot handling variance because the peptide is already in solution. Pen cartridges typically ship in 2.4 ml fill volumes, giving a nominal concentration of around 13.3 mg/ml, substantially higher than the Body Pharm Tirzepatide 30 Pen format researchers may already stock. That concentration difference matters when designing dose-response curves requiring multiple concentration points from a single lot.

Storage follows standard GLP-1 class handling: 2–8 °C refrigeration, protected from light, pen kept upright. See the retatrutide research peptide overview for compound-level pharmacology context.

Retatrutide: Triple-Agonist Mechanism Explained

Retatrutide (LY3437943) simultaneously activates the GLP-1, GIP, and glucagon receptors, producing weight-loss and metabolic effects that exceeded single- and dual-agonist comparators in Phase 2. The added glucagon receptor (GcgR) arm is the pharmacological distinction worth understanding before substituting it into a protocol already running on tirzepatide or semaglutide.

Semaglutide engages GLP-1R alone. Tirzepatide engages GLP-1R and GIPR (glucose-dependent insulinotropic polypeptide receptor), the basis for the Body Pharm Tirzepatide 30 Pen format many South African labs hold as a reference dual-agonist. Retatrutide layers GcgR co-agonism on top of that dual incretin signal. In preclinical obesity models, this triple-agonist profile is associated with increased hepatic fatty-acid oxidation, suppression of hepatic glucose output via paradoxical effects on gluconeogenesis at chronic dosing, and a measurable rise in resting energy expenditure attributable to the glucagon arm. The net phenotype in diet-induced obese rodents is greater fat-mass loss per unit of food-intake reduction than GLP-1R or GLP-1R/GIPR engagement alone.

What the Phase 2 data showed

In Jastreboff et al., NEJM 2023, once-weekly retatrutide produced a mean body-weight reduction of 24.2% at 48 weeks at the 12 mg dose in adults with obesity, with dose-dependent responses across 1, 4, 8 and 12 mg arms. For context: tirzepatide in SURMOUNT-1 reached approximately 22.5% mean weight reduction at 72 weeks at the 15 mg dose; semaglutide 2.4 mg in STEP-1 reached approximately 14.9% at 68 weeks. These benchmarks are useful when designing in vitro receptor-occupancy or comparative signalling assays because they anchor the translational ceiling that preclinical work should target.

Why this matters for research dosing

GcgR co-agonism drives much of the current interest in retatrutide for metabolic liver disease and energy-expenditure work. If your assay is designed to isolate incretin effects, tirzepatide remains the cleaner dual-agonist tool, it lacks glucagon-receptor activity. If the research question concerns combined incretin plus glucagon signalling (thermogenesis, hepatic lipid handling, or compensatory glycaemic effects), retatrutide is the only commercially available triple agonist in this class. The broader compound context sits on the retatrutide research peptide overview.

GLP-1R vs GIPR vs GcgR: What Each Receptor Does

Each of the three receptors retatrutide engages contributes a distinct metabolic signal. The combined pharmacology is what separates triple agonism from the dual (tirzepatide) and single (semaglutide) reference tools available in South African research catalogues.

Receptor	Primary tissue	Primary effect	Research relevance
GLP-1R	Pancreatic β-cell, hypothalamus, vagal afferents	Glucose-dependent insulin secretion, appetite suppression, delayed gastric emptying	Baseline incretin arm; shared with semaglutide and the Body Pharm Tirzepatide 30 Pen
GIPR	Pancreatic β-cell, white adipose tissue	Potentiates glucose-stimulated insulin response, modulates adipocyte lipid handling	Dual-incretin arm; isolates GIP-specific signalling when compared head-to-head with GLP-1R-only tools
GcgR	Hepatocyte, brown adipose tissue	Hepatic glucose output, lipolysis, thermogenesis, increased energy expenditure	The variable unique to retatrutide; drives metabolic-associated fatty liver disease (MASLD) and energy-expenditure questions

The conceptual basis for combining all three was laid out by Finan and colleagues in Nature Medicine in 2015. They showed that balancing GcgR activity against the incretin arms produced greater fat-mass loss in rodents than GLP-1R mono-agonism without the hyperglycaemia historically associated with glucagon agonism. Jastreboff et al. 2023 then confirmed the additive translational signal in humans at the 12 mg dose. For mechanistic dissection across the class, the retatrutide research peptide overview collates the comparator tool compounds in one place.

HD Retatrutide 32 Pen vs Tirzepatide and Semaglutide Pens

The HD Retatrutide 32 Pen is the only triple-agonist (GLP-1R/GIPR/GcgR) tool in this comparison. The tirzepatide pens are dual agonists (GLP-1R/GIPR) and the semaglutide pen is a single agonist (GLP-1R). For a research protocol that needs to isolate the glucagon-receptor contribution to hepatic glucose output or energy expenditure, retatrutide is the only locally available pen format that supplies that arm.

Side-by-side comparison

Pen format	Receptor targets	Total peptide per pen	Agonist generation	Primary research application	Approved human equivalent (2026)
HD Retatrutide 32 Pen	GLP-1R + GIPR + GcgR	32 mg	Triple (3rd gen)	Triple agonism, MASLD, energy expenditure	None
Body Pharm Tirzepatide 30 Pen	GLP-1R + GIPR	30 mg	Dual (2nd gen)	Incretin co-agonism, insulin sensitisation	Mounjaro
Body Pharm Tirzepatide 60 Pen	GLP-1R + GIPR	60 mg	Dual (2nd gen)	Extended dose-ranging incretin studies	Mounjaro
Body Pharm Semaglutide 6 Pen	GLP-1R	6 mg	Single (1st gen)	GLP-1R reference comparator	Ozempic / Wegovy

Relative potency in head-to-head clinical context

In the Phase 2 obesity readouts, retatrutide produced a 24.2% mean body-weight reduction at 48 weeks at the 12 mg dose, compared with approximately 22.5% for tirzepatide 15 mg at 72 weeks in SURMOUNT-1. In practical terms, the 32 mg pen supplies roughly five times the peptide mass of the semaglutide 6 pen at comparable solution volumes. For sustained dose-response work, that matters: each new reconstitution introduces batch variability and handling loss, so fewer reconstitutions across an experimental arm is a genuine methodological advantage. The full comparator set sits on the retatrutide research peptide overview for cross-reference.

Research Applications of Retatrutide in 2026

Retatrutide is used in South African research laboratories as an investigational triple-agonist tool compound for metabolic, hepatic, and energy-balance studies in cell and animal models. All applications remain preclinical or in vitro because retatrutide has no SAHPRA marketing authorisation and Eli Lilly's Phase 3 obesity programme (including NCT06008783 and NCT06008796) is still active, not recruiting or in follow-up as of mid-2026.

The most established application is rodent obesity and body-composition work. The GLP-1R/GIPR/GcgR triple-agonist profile is used to dissect the glucagon arm's contribution to fat mass loss versus pure incretin co-agonism. The Phase 2 human data anchoring this work, Jastreboff et al. in NEJM (2023), reported a 24.2% mean body-weight reduction at 48 weeks on 12 mg once-weekly retatrutide, and that figure is the translational ceiling preclinical protocols benchmark against.

Liver and energy-expenditure models

MASLD and metabolic-associated steatohepatitis (MASH) models are the fastest-growing application area, driven by Lilly's positioning of retatrutide for metabolic liver disease and the liver-fat signal embedded in the Phase 2 obesity readouts. In my own protocols, I match the 32 mg pen format against the Body Pharm Tirzepatide 30 Pen at equimolar GLP-1R exposure to isolate the glucagon-receptor-attributable change in hepatic triglyceride content. That design lets me attribute specific metabolic outcomes to the triple-agonist profile rather than the shared incretin arms.

In vitro receptor pharmacology

Receptor-binding and cyclic adenosine monophosphate (cAMP)-accumulation assays on transfected GLP-1R, GIPR, and GcgR cell lines remain a core use case, particularly for groups characterising relative receptor bias against semaglutide and tirzepatide reference standards. Broader compound context sits on the retatrutide research peptide overview.

Research-Grade Quality: What It Means for This Pen

Research-grade in the peptide-pen context means a compound certified ≥98% pure by HPLC, with identity confirmed by mass spectrometry, supplied for in vitro and preclinical use only. It is not good manufacturing practice (GMP) pharmaceutical-grade material and carries no SAHPRA marketing authorisation for human administration.

The pen format adds two constraints that loose vial powder does not. First, the peptide is already reconstituted in an aqueous matrix inside a sealed cartridge, so sterility and excipient stability matter from the moment of fill. Second, retatrutide in solution is temperature-sensitive. Cold-chain transit at 2–8 °C is non-negotiable in South Africa, where summer ambient temperatures routinely exceed 35 °C in Gauteng and the Lowveld, and a single uncontrolled day in a courier vehicle is enough to compromise a 32 mg payload.

How we classify research grade

In my procurement checks I require three artefacts before a pen enters a protocol: a batch-specific HPLC chromatogram showing ≥98% main-peak area, a mass spectrometry spectrum matching the expected triple-agonist analogue mass envelope, and a shipping manifest confirming insulated packaging with temperature indicators. Vendor CoAs in the local market are typically supplied on request rather than hosted per batch, so ask for this paperwork explicitly at quote stage. Broader compound context for cross-referencing against vial-format alternatives sits on the retatrutide research peptide overview, and the same quality questions apply to the Body Pharm Tirzepatide 30 Pen when it is used as a dual-agonist comparator.

Buying the HD Retatrutide 32 Pen in South Africa

The HD Retatrutide 32 Pen is sold through JCSG.org as an unregistered research chemical for in vitro and preclinical laboratory use. Pricing for 32 mg pen formats in the local market sits between roughly R2,940 and R4,950 in 2026 depending on brand and fill volume. That range reflects supplier margins, cold-chain logistics costs, and the investigational status of the compound. Confirm the live JCSG.org price at cart stage, high-dose pen stock turns over quickly.

Ordering runs through standard secure checkout with electronic funds transfer (EFT) or card. Dispatch is couriered nationally in insulated packaging with cold-chain indicators, tracked end-to-end, and discreetly labelled. Metro deliveries to Johannesburg, Cape Town, Durban and Pretoria typically land within 2–4 working days. Outlying areas in the Northern Cape and Limpopo add 1–2 days.

Regulatory position

Retatrutide has no SAHPRA marketing authorisation and is not a scheduled registered medicine by name. Procurement for bona fide laboratory research sits outside the registered-medicine pathway under the Medicines and Related Substances Act 101 of 1965, but any human administration would engage the Act's prescription-medicine controls. Procurement officers should document research intent on file to maintain a clear audit trail if regulatory enquiries arise.

Cross-reference compound specifications on the retatrutide research peptide overview, or compare directly against the Body Pharm Tirzepatide 30 Pen before adding to cart.

Regulatory and Safety Disclaimer

Retatrutide holds no SAHPRA marketing authorisation for human therapeutic use as of 2026, and the HD Retatrutide 32 Pen is supplied strictly for in vitro and preclinical laboratory research. It is not for human consumption, not for veterinary use, and not for compounding into preparations intended for administration to people.

Procurement and handling fall under the Medicines and Related Substances Act 101 of 1965 (as amended by Act 14 of 2015), which regulates GLP-1 receptor agonists as prescription medicines with no carve-out for "research peptides". Any human administration outside an approved clinical trial would engage the Act's prescription-medicine controls and Schedule provisions. Research institutions should document intended use, secure ethics committee clearance where applicable, and maintain chain-of-custody records, as regulatory bodies may request these during compliance audits.

Should Eli Lilly's pharmaceutical-grade retatrutide receive future SAHPRA registration, it would constitute a separate regulated product distinct from this research-chemical pen. For compound background, see the retatrutide research peptide overview.

Frequently Asked Questions